{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:17:12Z","timestamp":1760548632887,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejpb.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T19:31:05Z","timestamp":1687462265000},"page":"212-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanoparticulate impurities in the pharmaceutical excipient trehalose induce an early immune response"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-427X","authenticated-orcid":false,"given":"Jue","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejpb.2023.06.011_b0005","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1038\/cddis.2017.453","article-title":"Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development","volume":"8","author":"Tang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2023.06.011_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112577","article-title":"Assessment of in vitro kinetics and biological impact of nebulized trehalose on human bronchial epithelium","volume":"157","author":"Iskandar","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2023.06.011_b0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpb.2020.08.019","article-title":"Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray-drying: Trehalose\/amino acid combinations as reconstitution time reducing and stability improving formulations","volume":"156","author":"Massant","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.06.011_b0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-981-13-1244-1_20","article-title":"Applications of freezing and freeze-drying in pharmaceutical formulations","volume":"1081","author":"Izutsu","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejpb.2023.06.011_b0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-4615-0549-5_6","article-title":"Fundamentals of freeze-drying","volume":"14","author":"Nail","year":"2022","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.06.011_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpb.2018.02.002","article-title":"Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls","volume":"127","author":"Batens","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"28","key":"10.1016\/j.ejpb.2023.06.011_b0035","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"Anderson","year":"2019","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.011_b0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: An overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.011_b0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.011_b0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.011_b0055","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/jps.24573","article-title":"In vivo analysis of the potency of silicone oil microdroplets as immunological adjuvants in protein formulations","volume":"104","author":"Chisholm","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.xphs.2019.10.066","article-title":"Characterization of subvisible particles in biotherapeutic prefilled syringes: The role of polysorbate and protein on the formation of silicone oil and protein subvisible particles after drop shock","volume":"109","author":"Jiao","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.011_b0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.biologicals.2012.02.003","article-title":"Immunogenicity of recombinant human erythropoietin in Korea: a two-year cross-sectional study","volume":"40","author":"Shin","year":"2012","journal-title":"Biol.: J. Int. Assoc. Biol. Standard."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ki.2011.68","article-title":"Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies","volume":"80","author":"Praditpornsilpa","year":"2011","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.011_b0075","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1002\/jmv.27109","article-title":"N, Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine","volume":"93","author":"Abi Zeid Daou","year":"2021","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12539-021-00438-3","article-title":"Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunological Insights","volume":"13","author":"Selvaraj","year":"2021","journal-title":"Interdiscip. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.011_b0085","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jps.22097","article-title":"An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics","volume":"99","author":"Singh","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.011_b0090","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.011_b0095","first-page":"411","article-title":"Adverse drug reactions to biologics","volume":"8","author":"Scherer","year":"2010","journal-title":"J. Dtsch. Dermatol Ges."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, december 14\u201323, 2020","volume":"70","year":"2021","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"31","key":"10.1016\/j.ejpb.2023.06.011_b0105","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ejpb.2023.06.011_b0110","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1034\/j.1398-9995.2003.00279.x","article-title":"European Network for Drug Allergy (ENDA), EAACI interest group on drug hypersensitivity, Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations","volume":"58","author":"Aberer","year":"2003","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.ejpb.2023.06.011_b0115","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/ijms18071437","article-title":"Pro and contra: Provocation tests in drug hypersensitivity","volume":"18","author":"Soyer","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.ejpb.2023.06.011_b0120","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","article-title":"Safety-related regulatory actions for biologicals approved in the United States and the European Union","volume":"300","author":"Giezen","year":"2008","journal-title":"JAMA."},{"issue":"6524","key":"10.1016\/j.ejpb.2023.06.011_b0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1126\/science.371.6524.10","article-title":"COVID-19 Pfizer's vaccine raises allergy concerns","volume":"371","author":"Vrieze","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.011_b0130","first-page":"498","article-title":"Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result","volume":"127","author":"Pitlick","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0135","first-page":"99","article-title":"Polyethylene glycol and polysorbate testing in 12 patients before or after coronavirus disease 2019 vaccine administration","volume":"128","author":"Carpenter","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.011_b0140","first-page":"1533","article-title":"Phillips, immediate hypersensitivity to polyethylene glycols and polysorbates: More common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.ejpb.2023.06.011_b0145","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.jaip.2021.06.025","article-title":"PEG\/polysorbate skin testing has no utility in the assessment of suspected allergic reactions to SARS-CoV-2 vaccines","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cea.14064","article-title":"The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients","volume":"52","author":"Sellaturay","year":"2022","journal-title":"Clin. Exp. Allergy."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0155","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.xphs.2019.10.041","article-title":"Subvisible particles in IVIg formulations activate complement in human serum","volume":"109","author":"Chisholm","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2023.06.011_b0160","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/jps.24413","article-title":"Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice","volume":"104","author":"Shomali","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.011_b0165","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jps.21530","article-title":"Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality","volume":"98","author":"Carpenter","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.011_b0170","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/jps.22097","article-title":"T, Spitznagel, An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics","volume":"99","author":"Singh","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2023.06.011_b0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.biologicals.2015.07.011","article-title":"Subvisible (2\u2013100 \u03bcm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis","volume":"43","author":"Corvari","year":"2015","journal-title":"Biologicals"},{"issue":"12","key":"10.1016\/j.ejpb.2023.06.011_b0180","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s11095-017-2274-4","article-title":"Nanoparticulate impurities isolated from pharmaceutical-grade sucrose are a potential threat to protein stability","volume":"34","author":"Weinbuch","year":"2017","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0185","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41598-019-41171-8","article-title":"Evaluation of a new lymphocyte proliferation assay based on cyclic voltammetry; an alternative method","volume":"9","author":"Nikbakht","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.06.011_b0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.mie.2019.05.020","article-title":"CFSE dilution to study human T and NK cell proliferation in vitro","volume":"631","author":"Terr\u00e9n","year":"2020","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10837450.2014.982825","article-title":"Pre-filled syringes: a review of the history, manufacturing and challenges","volume":"20","author":"Sacha","year":"2015","journal-title":"Pharm. Dev. Technol."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0205","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.179.2.481","article-title":"\u201cAnergy\u201d of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype","volume":"179","author":"Gajewski","year":"1994","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.011_b0210","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.4049\/jimmunol.141.10.3445","article-title":"Characterization of T helper 1 and 2 cell subsets in normal mice. Helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells","volume":"141","author":"Swain","year":"1988","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1081-1206(10)62426-X","article-title":"T-cell subsets (Th1 versus Th2)","volume":"85","author":"Romagnani","year":"2000","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejpb.2023.06.011_b0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-94-017-9487-9_2","article-title":"TH1\/TH2 cell differentiation and molecular signals","volume":"841","author":"Zhang","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.011_b0225","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1189\/jlb.68.4.568","article-title":"Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells","volume":"68","author":"Yamamoto","year":"2000","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.011_b0230","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1080\/21645515.2019.1696075","article-title":"Significance of the IL-8 pathway for immunotherapy","volume":"16","author":"Gonzalez-Aparicio","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0192-0561(94)00088-6","article-title":"Interleukin-8 and the chemokine family","volume":"17","author":"Baggiolini","year":"1995","journal-title":"Int. J. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0240","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1215\/S1152851704001061","article-title":"The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis","volume":"7","author":"Brat","year":"2005","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.011_b0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","article-title":"Toxicity management for patients receiving novel T-cell engaging therapies","volume":"26","author":"Barrett","year":"2014","journal-title":"Curr. Opin. Pediatr."},{"issue":"26","key":"10.1016\/j.ejpb.2023.06.011_b0250","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood."},{"issue":"95","key":"10.1016\/j.ejpb.2023.06.011_b0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"26","key":"10.1016\/j.ejpb.2023.06.011_b0260","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejpb.2023.06.011_b0265","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.sdentj.2018.07.002","article-title":"MIP-1\u03b1 and MCP-1 as salivary biomarkers in periodontal disease","volume":"30","author":"Nisha","year":"2018","journal-title":"Saudi. Dent. J."},{"issue":"3","key":"10.1016\/j.ejpb.2023.06.011_b0270","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/jcb.27049","article-title":"MIP-1\u03b1 induces inflammatory responses by upregulating chemokine receptor 1\/chemokine receptor 5 and activating c-Jun N-terminal kinase and mitogen-activated protein kinase signaling pathways in acute pancreatitis","volume":"120","author":"Wu","year":"2019","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.ejpb.2023.06.011_b0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.resuscitation.2015.07.035","article-title":"Color-coded prefilled medication syringes decrease time to delivery and dosing errors in simulated prehospital pediatric resuscitations: A randomized crossover trial","volume":"96","author":"Stevens","year":"2015","journal-title":"Resuscitation"},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.annemergmed.2014.12.035","article-title":"Color-Coded Prefilled medication syringes decrease time to delivery and dosing error in simulated emergency department pediatric resuscitations","volume":"66","author":"Moreira","year":"2015","journal-title":"Ann. Emerg. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.011_b0285","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/bmjstel-2019-000437","article-title":"Intubation drug pack containing pre-filled syringes reduces the time to endotracheal intubation in a simulated paediatric emergency","volume":"6","author":"Lawson","year":"2020","journal-title":"BMJ Simul. Technol. Enhanc. Learn."},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.011_b0290","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1517\/17425247.2014.928281","article-title":"Extractables and leachables considerations for prefilled syringes","volume":"11","author":"Jenke","year":"2014","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:53:45Z","timestamp":1760547225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"alternative-id":["S0939641123001649"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.011","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticulate impurities in the pharmaceutical excipient trehalose induce an early immune response","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}